スタッフ紹介

学歴

1998年3月

北海道旭川東高等学校卒業

2004年3月

北海道大学医学部医学科卒業

2012年3月

北海道大学大学院医学研究科消化器内科学専攻医学博士課程修了

職務経歴

2004年4月

北海道大学病院　卒後臨床研修センター　初期研修医

2005年4月

市立函館病院　初期研修医

2006年4月

市立函館病院　消化器内科　医員

2007年4月

JA北海道厚生連網走厚生病院　内科・消化器科　医員

2008年4月

北海道大学病院　第三内科　医員

2009年4月

国立がん研究センター東病院　消化管内科　がん専門修練医

2011年4月

北海道大学病院　腫瘍センター　医員

2012年4月

市立函館病院　消化器内科　医員

2013年4月

NTT東日本札幌病院　消化器内科　医員

2015年4月

北海道大学病院　腫瘍センター　医員

2018年4月

北海道大学病院　消化器内科　特任助教

2020年4月

北海道大学病院　腫瘍センター　助教

所属学会・資格

• 日本内科学会　総合内科専門医
• 日本消化器病学会　専門医・指導医
• 日本臨床腫瘍学会　専門医・指導医
• 日本がん治療認定医機構　がん治療認定医
• 日本消化器内視鏡学会
• 日本緩和医療学会
• 日本胃癌学会
• 日本膵臓学会
• 日本胆道学会
• 日本遺伝性腫瘍学会
• American Society of Clinical Oncology （ASCO）
• European Society for Medical Oncology （ESMO）

趣味

読書、映画

研究費等

業績
（英文のみ）

1. Umemoto K, Sunakawa Y, Ueno M, Furukawa M, Mizuno N, Sudo K, Kawamoto Y, Kajiwara T, Ohtsubo K, Okano N, Matsuhashi N, Itoh S, Matsumoto T, Shimizu S, Otsuru T, Hasegawa H, Okuyama H, Ohama H, Moriwaki T, Ohta T, Odegaard JI, Nakamura Y, Bando H, Yoshino T, Ikeda M, Morizane C.
   Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer.
   Br J Cancer. 2023;128(8):1603-1608.
2. Harada K, Yamamura T, Muto O, Nakamura M, Sogabe S, Sawada K, Nakano S, Yagisawa M, Muranaka T, Dazai M, Tateyama M, Kobayashi Y, Kato S, Hatanaka K, Kawamoto Y, Yuki S, Sakata Y, Sakamoto N, Komatsu Y.
   Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101).
   J Clin Med. 2023;12(4).
3. Yoshida Y, Kobayashi S, Ueno M, Morizane C, Tsuji K, Maruki Y, Mori K, Watanabe K, Ohba A, Furuta M, Todaka A, Tsujimoto A, Ozaka M, Okano N, Yane K, Umemoto K, Kawamoto Y, Terashima T, Tsumura H, Doi K, Shioji K, Asagi A, Kojima Y, Suzuki E, Toshiyama R, Furukawa M, Naganuma A, Suzuki R, Miwa H, Ikeda M, Furuse J.
   Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
   Pancreatology. 2022;22(8):1159-1166.
4. Takada K, Kubo T, Kikuchi J, Yoshida M, Murota A, Arihara Y, Nakamura H, Nagashima H, Tanabe H, Sugita S, Tanaka Y, Miura A, Ohhara Y, Ishiguro A, Yokouchi H, Kawamoto Y, Mizukami Y, Ohnishi H, Kinoshita I, Sakurai A.
   Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: A prospective multicenter study.
   Front Oncol. 2022;12:988527.
5. Saito R, Kawamoto Y, Nishida M, Iwai T, Kikuchi Y, Yokota I, Takagi R, Yamamura T, Ito K, Harada K, Yuki S, Komatsu Y, Sakamoto N.
   Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.
   Int J Clin Oncol. 2022;27(11):1780-1790.
6. Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J, Hiraoka N, Yoshida H, Kuchiba A, Sadachi R, Nakamura K, Matsui N, Nakamura Y, Okamoto W, Yoshino T, Okusaka T.
   Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
   Future Oncol. 2022;18(19):2351-2360.
7. Nakatsumi H, Komatsu Y, Muranaka T, Yuki S, Kawamoto Y, Harada K, Dazai M, Tateyama M, Sasaki Y, Miyagishima T, Tsuji Y, Katagiri M, Nakamura M, Sogabe S, Hatanaka K, Meguro T, Kobayashi T, Ishiguro A, Muto O, Shindo Y, Kotaka M, Ando T, Takagi R, Sakamoto N, Sakata Y.
   Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
   Front Oncol. 2022;12:939425.
8. Nakamura M, Ishiguro A, Dazai M, Kawamoto Y, Yuki S, Sogabe S, Hosokawa A, Sawada K, Muto O, Izawa N, Nakashima K, Horie Y, Yagisawa M, Kajiura S, Ando T, Mitsuhashi Y, Sunakawa Y, Kikuchi Y, Komatsu Y.
   Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study.
   BMC Cancer. 2022;22(1):1322.
9. Komatsu Y, Shimokawa T, Akiyoshi K, Karayama M, Shimomura A, Kawamoto Y, Yuki S, Tambo Y, Kasahara K.
   An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors.
   Invest New Drugs. 2022;40(5):1011-1020.
10. Nakano S, Kawamoto Y, Komatsu Y, Saito R, Ito K, Yamamura T, Harada K, Yuki S, Kawakubo K, Sugiura R, Kato S, Hirata K, Hirata H, Nakajima M, Furukawa R, Takishin Y, Nagai K, Yokota I, Ota KH, Nakaoka S, Kuwatani M, Sakamoto N.
    Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived Samples.
    Pancreas. 2022;51(4):351-357.
11. Kawamoto Y, Yuki S, Sawada K, Nakamura M, Muto O, Sogabe S, Shindo Y, Ishiguro A, Sato A, Tsuji Y, Dazai M, Okuda H, Meguro T, Harada K, Sekiguchi M, Okada K, Ito M. Y, Sakata Y, Sakamoto N, Komatsu Y.
    Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
    Oncologist. 2022; DOI: 10.1093/oncolo/oyac086/6586834.
12. Nakano S, Kawamoto Y, Yuki S, Harada K, Miyagishima T, Sogabe S, Dazai M, Sato A, Ishiguro A, Nakamura M, Kajiura S, Takahashi Y, Tateyama M, Hatanaka K, Tsuji Y, Sasaki T, Shindo Y, Kobayashi T, Yokota I, Sakamoto N, Sakata Y, Komatsu Y.
    Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
    BMJ Open. 2022;12(5):e048833.
13. Kawamoto Y, Yuki S, Meguro T, Hatanaka K, Uebayashi M, Nakamura M, Okuda H, Iwanaga I, Kato T, Nakano S, Sato A, Harada K, Oba K, Sakata Y, Sakamoto N, Komatsu Y.
    Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
    Oncologist. 2022;27(5):340-e374.
14. Yamada I, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ueno M, Ikeda M, Okano N, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Tobimatsu K, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Okamura K, Yamashita T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J.
    The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
    Sci Rep. 2022;12(1):987.
15. Ito K, Yuki S, Nakatsumi H, Kawamoto Y, Harada K, Nakano S, Saito R, Ando T, Sawada K, Yagisawa M, Ishiguro A, Dazai M, Iwanaga I, Hatanaka K, Sato A, Matsumoto R, Shindo Y, Tateyama M, Muranaka T, Katagiri M, Yokota I, Sakata Y, Sakamoto N, Komatsu Y.
    
Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
Support Care Cancer. 2022;30(6):5351-5359.
16. Kawakami T, Masuishi T, Kawamoto Y, Go H, Kato K, Kumanishi R, Sawada K, Yuki S, Yamamoto K, Komatsu Y, Muro K, Fushiki K, Shirasu H, Yamazaki K.
    The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study.
    Cancer Med. 2022; DOI: 10.1002/cam4.4599.
17. Azemoto N, Ueno M, Yanagimoto H, Mizuno N, Kawamoto Y, Maruki Y, Watanabe K, Suzuki R, Kaneko J, Hisada Y, Sato H, Kobayashi S, Miyata H, Furukawa M, Mizukami T, Miwa H, Ohno Y, Tsuji K, Tsujimoto A, Nagano H, Okuyama H, Asagi A, Okano N, Ishii H, Morizane C, Ikeda M, Furuse J.
    Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study.
    Jpn J Clin Oncol. 2022;52(2):134-142.
18. Ueno M, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ikeda M, Ozaka M, Okano N, Sugimori K, Todaka A, Shimizu S, Mizuno N, Yamamoto T, Sano K, Tobimatsu K, Katanuma A, Miyamoto A, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Miyakawa H, Yamashita T, Yasuda I, Takahashi H, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J.
    Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.
    Sci Rep. 2021;11(1):12885.
19. Chida K, Kotani D, Masuishi T, Kawakami T, Kawamoto Y, Kato K, Fushiki K, Sawada K, Kumanishi R, Shirasu H, Matsubara Y, Yuki S, Komatsu Y, Yamazaki K, Yoshino T.
    The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study.
    Oncologist. 2021;26(10):845-853.
20. Kawamoto Y, Nakatsumi H, Harada K, Muranaka T, Ishiguro A, Kobayashi Y, Hayashi H, Yuki S, Sawada K, Yagisawa M, Nakano S, Sakamoto N, Komatsu Y.
    A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).
    Oncologist. 2021;26(10):e1675-1682.
21. Kato K, Masuishi T, Fushiki K, Nakano S, Kawamoto Y, Narita Y, Tsushima T, Harada K, Kadowaki S, Todaka A, Yuki S, Tajika M, Machida N, Komatsu Y, Yasui H, Muro K, Kawakami T.
    Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer.
    ESMO Open. 2021;6(4):100179.
22. Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, Ueno M, Kagawa Y, Nishina T, Kato T, Yamamoto Y, Furuse Junji, Denda T, Kawakami H, Oki Eiji, Nakajima T, Nishida N, Yamaguchi K, Yasui H, Goto M, Matsuhashi N, Ohtsubo K, Yamazaki K, Tsuji A, Okamoto W, Tsuchihara K, Yamanaka T, Miki I, Sakamoto Y, Ichiki H, Hata M, Yamashita R, Ohtsu A, Odegaard JI, Yoshino T.
    Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.
    Nat Med. 2020;26(12):1859-1864.
23. Sunakawa Y, Nakamura M, Ishizaki M, Kataoka M, Satake H, Kitazono M, Yanagisawa H, Kawamoto Y, Kuramochi H, Ohori H, Nakamura M, Maeda F, Komeno C, Sonezaki T, Takeuchi M, Fujii M, Yoshino T, Tsuji A, Ichikawa W.
    RAS mutations in circulating tumor DNA and clinical outcomes of rechallenge treatment with anti-EFGR antibodies in patients with metastatic colorectal cancer.
    JCO Precision Oncology. 2020;4:898-911.
24. Nakano S, Yuki S, Kawamoto Y, Nakatsumi H, Ando T, Kajiura S, Yoshikawa A, Harada K, Hatanaka K, Tanimoto A, Ishiguro A, Honda T, Dazai M, Sasaki T, Sakamoto N, Komatsu Y.
    Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
    Int J Clin Oncol. 2020;25(10):1800-1806.
25. Noji T, Nagayama M, Imai K, Kawamoto Y, Kuwatani M, Imamura M, Okamura K, Kimura Y, Hirano S.
    Conversion surgery for initially unresectable biliary malignancies: a multicenter retrospective cohort study.
    Surg Today. 2020;50(11):1409-1417.
26. Nakano S, Komatsu Y, Kawamoto Y, Saito R, Ito K, Nakatsumi H, Yuki S, Sakamoto N.
    Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer.
    Medicine (Baltimore). 2020;99(39):e22250.
27. Imaoka H, Ikeda M, Maehara K, Umemoto K, Ozaka M, Kobayashi S, Terashima T, Inoue H, Sakaguchi C, Tsuji K, Shioji K, Okamura K, Kawamoto Y, Suzuki R, Shirakawa H, Nagano H, Ueno M, Morizane C, Furuse J.
    Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
    BMC Cancer. 2020;20(1):946.
28. Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, Hara H, Mizuno N, Yanagimoto H, Wada K, Tobimatsu K, Yane K, Nakamori S, Yamaguchi H, Asagi A, Yukisawa S, Kojima Y, Kawabe K, Kawamoto Y, Sugimoto R, Iwai T, Nakamura K, Miyakawa H, Yamashita T, Hosokawa A, Ioka T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J.
    Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) Randomized Phase III Clinical Trial.
    Ann Oncol. 2019 Dec 1;30(12):1950-1958.
29. Harada K, Okamoto W, Mimaki S, Kawamoto Y, Bando H, Yamashita R, Yuki S, Yoshino T, Komatsu Y, Ohtsu A, Sakamoto N, Tsuchihara K.
    Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    BMC Cancer. 2019 Mar 21;19(1):255.
30. Sugiura R, Kuwatani M, Hirata K, Kato S, Kawamoto Y, Kawakubo K, Mitsuhashi T, Asano T, Hirano S, Sakamoto N.
    Synchronous multiple pancreatic cancers developed long after severe postendoscopic retrograde cholangiopancreatography pancreatitis.
    Endosc Ultrasound. 2019 Mar 12.
31. Masuishi T, Taniguchi H, Kawakami T, Kawamoto Y, Kadowaki S, Onozawa Y, Muranaka T, Tajika M, Yasui H, Nakatsumi H, Yuki S, Muro K, Omae K, Komatsu Y, Yamazaki K.
    Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    ESMO Open. 2019;4(6): DOI: 10.1136/esmoopen-2019-000584.
32. Yanagiya S, Cho KY, Nakamura A, Nomoto H, Kawamoto Y, Kawakubo K, Komatsu Y, Mitsuhashi T, Miyoshi H, Atsumi T.
    The effect of everolimus of refractory hypoglycemia in a patient with inoperable metastatic insulinoma evaluated by continuous glucose monitoring.
    Intern Med. 2018 Sep 1;57(17):2527-2531.
33. Kawamoto Y, Komatsu Y, Yuki S, Sawada K, Muranaka T, Harada K, Nakatsumi H, Fukushima H, Ishiguro A, Dazai M, Hatanaka K, Nakamura M, Iwanaga I, Uebayashi M, Sogabe S, Kobayashi Y, Miyagishima T, Ono K, Sakamoto N, Sakata Y.
    Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer.
    BMC Cancer. 2017 Dec;17(1):837.
34. Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, Yuki S, Kubota Y, Kubo K, Kawahata S, Kawakubo K, Kawakami H, Sakamoto N.
    Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
    J Gastrointest Oncol. 2017 Jun;8(3):566-571.
35. Muranaka T, Yuki S, Komatsu Y, Sawada K, Harada K, Kawamoto Y, Nakatsumi H, Sakamoto N.
    Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience.
    J Gastric Cancer. 2016 Sep;16(3):177-181. Epub 2016 Sep 30.
36. Kuwatani M, Kawamoto Y, Nakamura T.
    Eccentric Abscess Due to Bile Duct Microperforation Caused by Self-expandable Metal Stent and Neoadjuvant Chemoradiation.
    Clin Gastroenterol Hepatol 14. A29-30, 2016.
37. Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y.
    Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
    Cancer Sci. 2015 Jul;106(7):891-5.
38. Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M, Ochiai A, Bando H, Fuse N, Tahara M, Doi T, Esumi H, Komatsu Y, Ohtsu A.
    KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.
    Br J Cancer. 2012 Jul 10;107(2):340-4.
39. Ogasawara N, Bando H, Kawamoto Y, Yoshino T, Tsuchihara K, Ohtsu A, Esumi H.
    Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.
    Jpn J Clin Oncol. 2011 Jan;41(1):52-6.